Over the past six years, Dr. Teresa Lavoie has developed, managed, and overseen the sale of patent portfolios worth more than $33 billion in deal value. Her international practice focuses on strategic patent counseling, prosecution, and portfolio development advice, including patent opinions, due diligence, freedom-to-operate analyses, and life cycle management strategies. Dr. Lavoie’s clients range from start-up and emerging companies developing life-saving therapeutics and diagnostics to academic and research institutions inventing disruptive platform technologies for the biotechnology and biopharma industries. She has extensive experience in the areas of small-molecule and biologic pharmaceuticals (including antibody technologies and immunotherapies, such as CAR-T therapies), drug formulation and drug delivery technologies, diagnostics, clean and alternative (animal- and environmentally-friendly) food technologies, protein biochemistry and engineering, cell systems engineering, nanotechnologies, plant biotechnology and genomics, and green/environmental chemistries. Dr. Lavoie also has significant transactional experience in various aspects of IP licensing, including sponsored research, feasibility, and development and commercialization agreements.
Dr. Lavoie’s clients are located in the major biotechnology, academic/research institution, and start-up clusters around the country and the world, including San Francisco, Cambridge/Boston, and San Diego. Representative clients include: 10x Genomics, First Wave Bio, IFM Due, CytomX Therapeutics, Samumed, Cadent Therapeutics, Kyverna Therapeutics, Coherus BioSciences, Cellphire, Impossible Foods, Albireo Pharmaceuticals, Avanir Pharmaceuticals, Carmot Therapeutics, Concert Pharmaceuticals, Seattle Genetics, HCW Biologics, Pivot Bio, Chinook Therapeutics, Gasherbrum Bio, Annapurna Bio, Seelos Therapeutics, Array BioPharma (prior to its acquisition by Pfizer for $11.4B), IFM Therapeutics (prior to its acquisition by BMS for $2.2B), IFM Tre (prior to its acquisition by Novartis for $1.6B), Loxo Oncology (prior to acquisition by Eli Lilly for $8 billion), and Onyx Pharmaceuticals (prior to acquisition by Amgen for $9.7 billion).
In addition to her work on behalf of clients, Dr. Lavoie runs the firm’s industry-leading Patent Prosecution Boot Camp, an immersive 2.5-day program designed to intensely train junior attorneys and patent agents of the firm and firm clients in the skills of strategic and value-focused patent prosecution.
Dr. Lavoie’s passion for advancing women in the legal industry and her involvement in the recruitment, retention, and advancement of women in both STEM and law has been a hallmark of her legal practice and volunteer commitments throughout her career. For three years, she chaired Fish & Richardson’s EMPOWER (Enrichment, Mentorship, Partnering, Opportunities, Wisdom, Excellence, and Responsibility) Initiative, which seeks to address issues of unique importance to women in the legal profession. She has also been a member of the firm’s Compensation Committee for four years. In addition, Dr. Lavoie serves as Co-Chair of the Equity Committee for Minnesota Women Lawyers, a volunteer organization dedicated to advancing the success of women attorneys and striving for a just society.
Recently, Dr. Lavoie endowed The Anna E. Lavoie Memorial Lectureship at Providence College in tribute to her late mother. Its purpose is to encourage undergraduates to consider a wide array of career paths in the sciences through interaction with distinguished scientists and other professionals. She is also an Adjunct Professor at the University of Minnesota Law School, teaching Biotechnology Patent Law.
Prior to joining Fish, Dr. Lavoie worked as an Intellectual Property Specialist for Epix Pharmaceuticals, Inc. (1996-2000), as a Special Projects Coordinator for Environmental Waste Management Associates, Inc. (1995-1996), and as a Research Assistant at Princeton University (1990-1995).
February 11, 2020
Fish Named Law360 Life Sciences Practice Group of the Year
February 21, 2019
Fish & Richardson’s Dr. Teresa Lavoie Receives 2019 “Diversity Leader” Award
July 30th, 2020 | 1:30 pm EDT
Webinar | Structuring Biotech & Pharma Startup Portfolios for Global Impact, Value, and Partnering
July 21st, 2020 | 1:30 pm EDT
Webinar | Navigating to the Safe Harbor: What to Know in Advance
June 8, 2020
Teresa Lavoie & Chad Shear Author Article in The Recorder: "The Data Room in Patent Due Diligence: Perspectives from Two Doors"
May 7, 2020
Jay Kugler DeYoung Named Chair of Fish & Richardson’s EMPOWER Women’s Initiative
February 7, 2020
Fish & Richardson Principal Teresa Lavoie Profiled in Minnesota Lawyer
January 27, 2020
Teresa Lavoie Named a 2019 Attorney of the Year by Minnesota Lawyer
January 2, 2020
Fish & Richardson's Teresa Lavoie Quoted in “Pharma IP Summit: Timing of the Essence When Filing Patents”
October 2, 2019
Fish & Richardson Receives Top Firm Rankings from LMG Life Sciences in Four Practice Areas
June 20, 2019
Fish & Richardson Receives Top “Gold” Ranking from IAM Patent 1000 for National Patent Litigation Practice
May 22, 2019
Fish & Richardson Announces 32 Attorneys Named “IP Stars” by Managing Intellectual Property Magazine